Bendamustine

證據等級: L5

預測適應症: 10 個

Bendamustine: From Chronic Lymphocytic Leukemia / Indolent B-Cell NHL to Mantle Cell Lymphoma

One-Sentence Summary

Bendamustine is a bifunctional alkylating agent with a unique dual mechanism — inducing DNA alkylating cross-links while also bearing a benzimidazole ring that confers partial antimetabolite properties — and has been established clinically for chronic lymphocytic leukemia (CLL) and rituximab-refractory indolent B-cell non-Hodgkin lymphoma (NHL). The TxGNN model predicts it may be highly effective for Mantle Cell Lymphoma (MCL), with multiple completed and ongoing Phase 3 clinical trials and 20 publications currently supporting this direction — evidence level L1, the highest tier available.

Quick Overview

Item	Content
Original Indication	Chronic lymphocytic leukemia; Rituximab-refractory indolent B-cell non-Hodgkin lymphoma (based on clinical literature; no US NDA records found in database)
Predicted New Indication	Mantle Cell Lymphoma
TxGNN Prediction Score	99.63%
Evidence Level	L1 (multiple completed Phase 3 RCTs)
US Market Status	Not found in database (0 records retrieved; potential data collection gap)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Formal MOA data is not populated in this Evidence Pack. However, multiple publications within the evidence pack itself provide mechanistic context. Bendamustine is a bifunctional alkylating agent structurally unique among its class: the nitrogen mustard moiety generates DNA interstrand cross-links and double-strand breaks, while the benzimidazole ring mimics purine nucleosides and interferes with DNA synthesis — a partial antimetabolite effect. This dual mechanism produces only partial cross-resistance with conventional alkylating agents such as cyclophosphamide or cisplatin, explaining activity in tumors refractory to standard chemotherapy (PMID 11368287, 25829094).

MCL is a biologically aggressive mature B-cell lymphoma driven by t(11;14)-mediated cyclin D1 overexpression, constitutive BCR signaling, and — especially in high-risk variants — defects in the ATM/TP53 DNA damage response pathway. Cells with impaired DNA repair are precisely the most vulnerable to agents inducing double-strand breaks. The repurposing rationale in this evidence pack states explicitly: “MCL is highly dependent on BCR signaling and DNA repair defects, conferring high sensitivity to alkylating agents.” Bendamustine’s purine analog scaffold may additionally bypass resistance mechanisms that limit classical alkylators in these cells.

Importantly, this TxGNN prediction does not represent a speculative future use — it identifies a direction that is already well-established in clinical practice. The Phase 3 StiL trial (Rummel 2013, Lancet) and the SHINE trial (Wang 2022, NEJM) have firmly positioned BR (bendamustine + rituximab) as a standard first-line chemotherapy backbone for MCL. Current EHA guidelines (2025, HemaSphere) endorse BR for transplant-ineligible patients, and multiple ongoing Phase 3 trials continue to use BR as the control arm against which novel agents are tested. The TxGNN model correctly capturing this as a top-ranked indication validates the algorithm’s ability to reflect real-world clinical consensus.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01776840	Phase 3	Completed	523	SHINE trial: Ibrutinib + BR vs placebo + BR in untreated MCL (≥65 years). Pivotal double-blind RCT establishing BR as the standard chemotherapy backbone for older MCL patients; IBR significantly prolonged PFS
NCT00991211	Phase 3	Completed	549	StiL trial: BR vs R-CHOP as first-line therapy for indolent NHL and MCL. Demonstrated BR is non-inferior to R-CHOP in PFS with improved tolerability; landmark trial defining BR standard of care
NCT02972840	Phase 3	Active, Not Recruiting	635	Acalabrutinib + BR vs placebo + BR in previously untreated MCL. Double-blind Phase 3 RCT; confirms BR as active control and evaluates next-generation BTKi combination
NCT06363994	Phase 3	Recruiting	476	Orelabrutinib + BR vs BR in treatment-naïve MCL. Double-blind Phase 3 RCT; BR serves as randomized control arm, further cementing its standard role
NCT06084936	Phase 3	Recruiting	182	Glofitamab monotherapy vs investigator’s choice (BR or R-Lenalidomide) in R/R MCL. BR is designated standard-of-care comparator arm for relapsed/refractory setting
NCT06496308	Phase 3	Recruiting	78	Orelabrutinib + BR vs BR in transplant-ineligible intermediate/high-risk MCL. Directly compares BR ± BTK inhibitor in a defined high-risk subpopulation
NCT00992134	Phase 2	Completed	41	R-BAC (Rituximab + Bendamustine + Cytarabine) in MCL patients ≥65 years or ineligible for intensive therapy. Directly demonstrates bendamustine-containing regimen efficacy and safety in this population
NCT01662050	Phase 2	Completed	57	Age-adjusted R-BAC induction in older MCL patients. Evaluates tolerability-optimized bendamustine dosing; supports dose individualization in elderly patients
NCT06136351	Phase 2	Recruiting	23	Zanubrutinib + BR in elderly or TP53-mutated newly diagnosed MCL. Addresses the high-risk subgroup where cytotoxic backbone remains essential
NCT04127916	N/A (Retrospective)	Unknown	40	Korean multicenter retrospective analysis of BR in R/R MCL. Real-world efficacy and safety data from Asian clinical practice

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35657079	2022	Phase 3 RCT	New England Journal of Medicine	SHINE trial: Ibrutinib + BR prolonged median PFS (80.6 vs 52.9 months) vs BR alone in older untreated MCL; confirms BR as the foundational backbone against which all novel agents are measured
40311141	2025	Phase 3 RCT	Journal of Clinical Oncology	Acalabrutinib + BR in untreated MCL; next-generation BTKi + BR demonstrates favorable efficacy-toxicity profile compared to ibrutinib-based combination
23433739	2013	Phase 3 RCT	Lancet	StiL trial: BR non-inferior to R-CHOP in first-line MCL and indolent lymphoma, with significantly lower rates of alopecia, infections, and peripheral neuropathy; landmark trial that redefined MCL first-line therapy
30811293	2019	Phase 3 / Prospective Cohort	Journal of Clinical Oncology	BRIGHT 5-year follow-up: BR maintains durable remission vs R-CHOP/R-CVP in treatment-naïve indolent NHL and MCL; confirms long-term efficacy of BR backbone
41132246	2025	Clinical Guideline	HemaSphere	EHA-EU MCL network guidelines: BR endorsed as standard first-line chemoimmunotherapy for transplant-ineligible patients; current consensus document from European experts
41052510	2025	Phase 2/3 RCT	Lancet	ENRICH trial: Ibrutinib-rituximab (chemotherapy-free) vs immunochemotherapy (R-CHOP or BR) in older untreated MCL; BR remains one of two standard comparator regimens
36919283	2023	Network Meta-analysis	European Journal of Haematology	Network meta-analysis of 3 RCTs (n=1,459): Ibrutinib + BR ranked superior to BR alone in PFS for transplant-ineligible untreated MCL; quantifies incremental benefit of BTKi addition over BR
36456154	2022	Retrospective Cohort	Anticancer Research	Korean multicenter retrospective: BR demonstrates high efficacy in both treatment-naïve and R/R MCL in real-world Asian clinical practice; confirms generalizability beyond trial populations
32126141	2020	Retrospective Cohort	Blood Advances	Pooled analysis of two Phase 2 trials: alternating RB + RC (rituximab/bendamustine + rituximab/high-dose cytarabine) followed by ASCT in transplant-eligible MCL; bendamustine induction is effective pre-transplant bridge
26755518	2016	Review	Journal of Clinical Oncology	Comprehensive MCL disease review: identifies bendamustine maintenance rituximab and BR combination as key advances improving outcomes in older patients over the prior decade

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Bifunctional alkylating agent (nitrogen mustard derivative with benzimidazole ring; exhibits partial antimetabolite activity through purine analog structural mimicry)
Myelosuppression Risk	High — Neutropenia, thrombocytopenia, and profound lymphopenia are well-documented; prolonged T-cell depletion (CD4+ and CD8+) persists for months after treatment, substantially increasing risk of opportunistic infections including Pneumocystis jirovecii pneumonia and viral reactivation (HSV, VZV, CMV)
Emetogenicity Classification	Low to moderate (MASCC/ESMO classification: minimal to low emetogenic potential; oral 5-HT₃ antagonist prophylaxis generally sufficient)
Monitoring Items	CBC with differential (before each cycle and as clinically indicated); hepatic function (AST, ALT, bilirubin); renal function (serum creatinine); signs and symptoms of infection; CD4+ lymphocyte count in high-risk patients for opportunistic infection prophylaxis guidance
Handling Protection	Cytotoxic drug handling regulations apply in all settings; preparation must be performed in a biological safety cabinet (Class II or higher); closed-system drug transfer devices (CSTDs) are strongly recommended; personnel must wear appropriate PPE per institutional cytotoxic handling policy

Safety Considerations

Please refer to the package insert for safety information.

No key warnings, contraindications, or drug interaction data were retrieved in this Evidence Pack. The safety data fields for TFDA package insert content and DDI records returned no results. Full safety review requires downloading and parsing the originator product label (Treanda®/Bendeka®) from the US FDA website.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs (including the landmark StiL trial and SHINE trial) directly establish BR as a standard-of-care backbone for MCL, endorsed by current EHA guidelines (2025). The mechanistic link is sound — MCL’s DNA repair deficiency renders it highly sensitive to the double-strand break-inducing activity of bendamustine — and the TxGNN prediction at 99.63% is fully consistent with established clinical consensus. Evidence quality reaches the highest tier (L1).

To proceed, the following is needed:

US FDA NDA verification: Database returned 0 records for bendamustine, which is inconsistent with known Treanda® (NDA 022249) and Bendeka® (NDA 207491) approvals; data pipeline for US regulatory records requires investigation and correction
Formal MOA documentation: DrugBank API query should be re-run to populate the original_moa field and complete the mechanistic analysis section
Package insert safety review: Obtain and parse the FDA-approved labeling for bendamustine (Treanda/Bendeka) to populate key warnings, contraindications, black box warnings (myelosuppression, infection, secondary malignancies, embryo-fetal toxicity), and drug interaction data
Opportunistic infection prophylaxis protocol: Given profound T-cell lymphopenia, a monitoring and prophylaxis plan (PCP prophylaxis, antiviral prophylaxis, CMV monitoring) should be established before clinical deployment
Taiwan regulatory pathway assessment: Bendamustine is not registered in Taiwan (未上市); if deployment in Taiwan is planned, a regulatory strategy for local approval or special access program is required
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.